BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sarl (NASDAQ: CELG) today announced that amrubicin hydrochloride has been designated as an orphan medicinal product by the European Commission (EC) for the treatment of small cell lung cancer following the favorable opinion of the European Medicines Agency’s (EMEA) Committee for Orphan Medicinal Products (COMP).
